FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Direct Rx Duloxetine D/R Recall

Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Di…

Direct Rx · Dawsonville, GA

Risk level
Class II
Reported by FDA
Aug 13, 2025
Recall ID
D-0567-2025
Check your lot numberHow we source this data

Summary

Direct Rx recalled Duloxetine D/R starting Mar 7, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0567-2025 on Aug 13, 2025. Reason: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Product description

Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30

Lot numbers, UPCs & expiration codes

Lot #: 02AU2406, Exp 01/31/2027

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0567-2025
Classification
Class II
Status
Ongoing
Recall initiated
Mar 7, 2025
FDA report date
Aug 13, 2025
Quantity
16 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Direct Rx

Original FDA data

Every field from FDA enforcement report D-0567-2025, exactly as published.

Show all FDA fields
City
Dawsonville
State
GA
Status
Ongoing
Country
United States
Event ID
97251
Address
94 Worldwide Dr
Code information
Lot #: 02AU2406, Exp 01/31/2027
Postal code
30534-6828
Report date
Aug 13, 2025
Product type
Drugs
Recall number
D-0567-2025
Classification
Class II
Recalling firm
Direct Rx
Product quantity
16 bottles
Reason for recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30
Distribution pattern
Nationwide
Recall initiation date
Mar 7, 2025
Initial firm notification
Letter
Center classification date
Aug 4, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0567-2025, published Aug 13, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls